Annual report
9987.TEDINET S100TQTQ
Period2023-04-01 → 2024-03-31
Filed2024-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.39T | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥2.31T | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥2.24T | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.13T | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.21T | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥34.9bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥32.6bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥38.4bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥36.4bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥23.4bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.3bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥41.5bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥42.8bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥30.6bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥29.0bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥20.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥14.4bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥7.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥28.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥29.0bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥20.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥1.23T | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.15T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.14T | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.11T | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.11T | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥812.3bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥734.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥416.4bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥411.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥418.1bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥417.9bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥412.7bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥181.8bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥109.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥198.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥132.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥168.2bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥168.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥175.2bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥87.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥37.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥9.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥15.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥25.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥10.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥46.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥14.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥31.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥26.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥11.6bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥7.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥17.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥357.88 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥236.47 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥163.19 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥88.52 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥310.26 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥5,361.96 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,970.38 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,749.59 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,675.23 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,618.33 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 33.9% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.4% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.0% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 7.0% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.9% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.4% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 1.9% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 13,086 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 13,429 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 14,032 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 15,041 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 15,477 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥2.19T | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥2.12T | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥2.04T | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.93T | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.00T | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥23.6bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥20.3bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥28.5bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥24.7bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥14.9bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥11.8bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥30.7bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥31.3bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥20.8bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥21.1bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥14.9bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥13.8bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥6.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥21.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.13T | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥1.05T | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥1.03T | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.00T | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.00T | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥846.4bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥758.9bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥286.6bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥290.8bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥302.5bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥303.2bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥301.0bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥141.4bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥63.5bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥259.73 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥172.97 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥156.55 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.15 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥238.38 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥80 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,691.98 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,515 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,440.25 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,398.64 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,375.27 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 25.3% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.7% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.5% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.2% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.0% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 7.3% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.6% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.0% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 77,740,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 82,831,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 103,344,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 103,344,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 103,344,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 3,176 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 3,232 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 3,430 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 4,116 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 4,244 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 75
| Segment | Item | Period | Value |
|---|---|---|---|
| The Community Healthcare And Nursing Care Support Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥851m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | employees | at 2024-03-31 | 3574 pure |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥97.5bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥97.4bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥19m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | segment assets | at 2024-03-31 | ¥42.5bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.7bn |
| The Healthcare Product Development Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥481m |
| The Healthcare Product Development Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥515m |
| The Healthcare Product Development Businessreportable segment | employees | at 2024-03-31 | 878 pure |
| The Healthcare Product Development Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥51.3bn |
| The Healthcare Product Development Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥11.9bn |
| The Healthcare Product Development Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥39.4bn |
| The Healthcare Product Development Businessreportable segment | segment assets | at 2024-03-31 | ¥63.4bn |
| The Healthcare Product Development Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| The Healthcare Related Services Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥57m |
| The Healthcare Related Services Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥545m |
| The Healthcare Related Services Businessreportable segment | employees | at 2024-03-31 | 647 pure |
| The Healthcare Related Services Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥261.6bn |
| The Healthcare Related Services Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥28.7bn |
| The Healthcare Related Services Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥232.9bn |
| The Healthcare Related Services Businessreportable segment | segment assets | at 2024-03-31 | ¥73.7bn |
| The Healthcare Related Services Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| The Pharmaceutical Distribution Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥14.2bn |
| The Pharmaceutical Distribution Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥6.7bn |
| The Pharmaceutical Distribution Businessreportable segment | employees | at 2024-03-31 | 7987 pure |
| The Pharmaceutical Distribution Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.30T |
| The Pharmaceutical Distribution Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.25T |
| The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥50.8bn |
| The Pharmaceutical Distribution Businessreportable segment | segment assets | at 2024-03-31 | ¥1.08T |
| The Pharmaceutical Distribution Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥30.4bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥15.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥8.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥2.71T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥2.39T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥323.1bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥1.26T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥34.8bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥783m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥782m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥98.0bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥98.0bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥18m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | segment assets | at 2023-03-31 | ¥43.5bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.6bn |
| The Healthcare Product Development Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥504m |
| The Healthcare Product Development Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥654m |
| The Healthcare Product Development Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥47.4bn |
| The Healthcare Product Development Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥11.6bn |
| The Healthcare Product Development Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥35.8bn |
| The Healthcare Product Development Businessreportable segment | segment assets | at 2023-03-31 | ¥63.8bn |
| The Healthcare Product Development Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.6bn |
| The Healthcare Related Services Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥881m |
| The Healthcare Related Services Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥505m |
| The Healthcare Related Services Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥215.4bn |
| The Healthcare Related Services Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥28.2bn |
| The Healthcare Related Services Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥187.2bn |
| The Healthcare Related Services Businessreportable segment | segment assets | at 2023-03-31 | ¥69.3bn |
| The Healthcare Related Services Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| The Pharmaceutical Distribution Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥15.6bn |
| The Pharmaceutical Distribution Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥6.7bn |
| The Pharmaceutical Distribution Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥2.23T |
| The Pharmaceutical Distribution Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥2.18T |
| The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥49.9bn |
| The Pharmaceutical Distribution Businessreportable segment | segment assets | at 2023-03-31 | ¥972.0bn |
| The Pharmaceutical Distribution Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥27.1bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥17.7bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥8.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥2.59T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥2.31T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥272.9bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥1.15T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥32.3bn |
| The Pharmaceutical Distribution Businessreportable segment | employees | at 2024-03-31 | 3176 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,090
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人ト ー マ ツ | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)西 松 真 人 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)増 見 彰 則 | |
| Cpa3 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)石 原 由 寛 | |
| Key audit matters consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)製薬企業から受取る仕入割戻 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row2Member | Original text (Japanese)独占禁止法関連損失引当金の見積計上 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row2Member | Text · Plus | |
| Reference2 kam consolidated | FilingDateInstant_Row2Member | Original text (Japanese)重要な会計上の見積り | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Other information consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information consolidated (text) | FilingDateInstant | Text · Plus | |
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人ト ー マ ツ | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)西 松 真 人 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)増 見 彰 則 | |
| Cpa3 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)石 原 由 寛 | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)製薬企業から受取る仕入割戻 | |
| Same as kam for consolidated fskam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior4YearDuration | 2213478000000 | JPY |
| Net sales (5-year summary) | Prior3YearDuration | 2128218000000 | JPY |
| Net sales (5-year summary) | Prior2YearDuration | 2239112000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 2314828000000 | JPY |
| Net sales (5-year summary) | CurrentYearDuration | 2386493000000 | JPY |
| Ordinary income loss (5-year summary) | Prior4YearDuration | 41467000000 | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration | 18272000000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration | 23418000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 36376000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration | 38351000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior4YearDuration | 28213000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior3YearDuration | 7895000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior2YearDuration | 14393000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 20345000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYearDuration | 29016000000 | JPY |
| Comprehensive income (5-year summary) | Prior4YearDuration | 27597000000 | JPY |
| Comprehensive income (5-year summary) | Prior3YearDuration | 12010000000 | JPY |
| Comprehensive income (5-year summary) | Prior2YearDuration | 11158000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 19170000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYearDuration | 36230000000 | JPY |
| Net assets (5-year summary) | Prior4YearInstant | 412708000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |